Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension study of ORADUR-Methylphenidate in pediatric ADHD
NCT02704390Phase 3Completed
- Sponsor
- Orient Pharma Co., Ltd.
- Start
- Jan 2016
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of methylphenidate in attention deficit hyperactivity disorder (ADHD), sponsored by Orient Pharma Co., Ltd.. Started Jan 2016; status: completed.
02
Drugs
methylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT02704390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02704390.